Anti-hypertensive Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Anti-hypertensive Drugs market is segmented by Therapeutic Class (Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Beta Blockers, Alpha Blockers, Renin Inhibitors, Calcium Channel Blockers, and Other Therapeutic Classes), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Anti-hypertensive Drugs Market Snapshot

Anti-hypertensive Drugs Market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 4.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The anti-hypertensive drugs market is expected to register a CAGR of 4.5% during the forecast period (2021 to 2026).

The COVID-19 pandemic had a severe impact on people with any kind of comorbidity including hypertension. Also, due to lockdown and other restrictions placed to curb the spread of the infection from the SARS-CoV-2 virus, the lifestyle of patients with hypertension was severely impacted. As per the July 2020 report from the American College of Cardiology, the early report from the COVID-19 hotspots like Wuhan, Lombardy, and New York City showed that people with hypertension were among the severely ill and hospitalized COVID-19 patients which in turn expected to boost the growth of the anti-hypertensive drugs market.

One of the leading factors responsible for the growth of the anti-hypertensive drugs market is the rising prevalence of hypertension among people around the world. The major known causes of hypertension are kidney diseases, diabetes, obstructive sleep apnea, and other cardiovascular diseases due to which the prevalence of hypertension has been observed a significant rise over the past few years. Also, some drugs can induce hypertension in patients with other diseases or disorders which in turn is expected to promote the growth of the studied market. As per the updated May 2021 data from the World Health Organization, about 1.13 billion people around the world have hypertension, of which two-third are living in low- and middle-income countries. In the report published in June 2020 titled “A Global View on Prevalence of Hypertension and Human Development Index” to determine the relationship between the prevalence of hypertension and human development index (HDI) concluded that the prevalence of hypertension ranged from 35 to 41% among 182 countries around the world. Thus, the rising prevalence of hypertension is expected to drive the growth of the anti-hypertensive drugs market.

Certain other factors that will boost the growth of the anti-hypertensive drugs market include growing initiatives by private and government organizations and rising awareness about hypertension around the around. For instance, in July 2020, Glenmark Pharmaceuticals launched the world’s first hypertension awareness symbol backed by the Association of Physicians of India (API) and Hypertension Society of India (HIS).

Whereas factors such as expiration of patent of multiple major drugs along with side effects associated with the hypertension treatment and rise in the availability of other non-pharmacological based therapy will restrict the growth of the anti-hypertensive drugs market. For example, as per AbbVie, the parent company of Allergan, the patent of its anti-hypertensive drug, Bystolic (Nebivolol) is expiring in December 2021.

Scope of the Report

As per the scope of the report, anti-hypertensive drugs are referred to as a class of drugs that are used in the treatment of hypertension (high blood pressure) disorder. There are many classes of anti-hypertensive drugs which can reduce blood pressure by different means, and thus, preventing the complications associated with high blood pressure, including stroke and myocardial infarction. The Anti-hypertensive Drugs market is segmented by therapeutic class (diuretics, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta blockers, alpha blockers, renin inhibitors, calcium channel blockers, and other therapeutic classes), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

Therapeutic Class
Diuretics
Angiotensin Converting Enzyme (ACE) Inhibitors
Angiotensin Receptor Blockers (ARBs)
Beta Blockers
Alpha Blockers
Renin Inhibitors
Calcium Channel Blockers
Other Therapeutic Classes
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Diuretics Therapeutics Class is Expected to Hold a Significant Market Share in the Forecast Period

Mostly all the monogenic forms of hypertension have sodium retention as the main mechanism of the increase in blood pressure or hypertension. Diuretics help in reducing the sodium and water from the body by inducing kidneys to release more sodium into the urine which leads to lower blood pressure as fluid flowing through the body is decreases. Diuretics are the preferred class of therapeutic drugs for the treatment of hypertension over others mainly because of their high efficacy, low cost, and low chances of side effects as compared to other available therapeutic classes in the anti-hypertensive drugs market.

Diuretics are of three types - thiazide diuretics, loop diuretics, and potassium-sparing diuretics, from which thiazide diuretics are the cornerstone of treatment for hypertension in most patients around the world. For instance, as per the research article published in August 2019, titled “Redefining Diuretics Use in Hypertension: Why Select a Thiazide like Diuretic?”, diuretics are listed as first-line treatment options in the hypertension treatment guidelines throughout the world mainly due to their effectiveness in acting against the mechanism that causes high blood pressure.

Also, in the United States, the Joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure recommends thiazide-type diuretics to be one of the preferred drug treatments for hypertension, whether used on its own or along with other antihypertensive drugs, such as calcium channel blockers. Therefore, owing to the above-mentioned factors, the diuretics therapeutics class is expected to have highest growth as compared to others with the rise in the prevalence of hypertension cases around the world.

Regional

North America is Expected to Dominate the Anti-hypertensive Drugs Market Over the Forecast Period

North America holds a major share in the anti-hypertensive drugs market and is expected to show a similar trend over the forecast period mainly due to the high prevalence of hypertension and diseases causing hypertension in the region. Additionally, the demand for prompt and accurate diagnosis and treatment of hypertension, identifying people predisposed to the disease, presence of technically advanced healthcare infrastructure, and management of the prognosis of the disease are some of the key market drivers of the North American anti-hypertension market.

In North America, the United States will hold the largest market in anti-hypertensive drugs market in the region. In the United States, the rising prevalence of hypertension is the major reason for the growth of the anti-hypertensive drugs market. As per the April 2020 data of the National Center for Health Statistics, the prevalence of age-adjusted hypertension in the United States was 45.4% in adults and was 51% in men and 39.7% in women during the survey period of 2017-2018. Also, as per the report, the prevalence of hypertension decreased from 47% in 1999-2000 to 41.7% in 2013-2014, and then again increased to 45.4% in 2017-2018. The other factors such as increasing awareness among the people about hypertension and new product launches by the pharmaceutical companies in the region. For instance, in November 2018, Dr Reddy’s Laboratories launched anti-hypertensive drug, Chlorthalidone tablets in the United States market for the treatment of high blood pressure. Thus, the North America is expected to hold major market share in the anti-hypertensive market.

Global

Competitive Landscape

The anti-hypertensive drugs market is highly competitive due to the presence of a number of pharmaceutical companies. Companies such as AstraZeneca PLC, C.H. Boehringer Sohn AG & Ko. KG, Daiichi Sankyo Company Limited, Johnson & Johnson Ltd, Lupin Limited, Merck & Co. Inc., Novartis AG, among others, hold a substantial market share in the anti-hypertensive drugs market.

Recent Developments

In April 2021, United Therapeutics Corporation announced that the United States Food and Drug Administration approved its drug for the treatment of pulmonary hypertension associated with interstitial lung disease, known as Tyvaso (Treprostinil).

In February 2021, Hanmi Pharmaceuticals announced the launch of a 4-ingredient drug combo for the treatment of hypertension and hyperlipidemia, called Amosartan XQ 

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Hypertension

      2. 4.2.2 Growing Initiatives by Private and Government Organizations

      3. 4.2.3 Rising Awareness about Hypertension

    3. 4.3 Market Restraints

      1. 4.3.1 Multiple Major Drug Patent Expiration

      2. 4.3.2 Side-effects of Treatment Options and Rise in Non-pharmacological Therapy

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Therapeutic Class

      1. 5.1.1 Diuretics

      2. 5.1.2 Angiotensin Converting Enzyme (ACE) Inhibitors

      3. 5.1.3 Angiotensin Receptor Blockers (ARBs)

      4. 5.1.4 Beta Blockers

      5. 5.1.5 Alpha Blockers

      6. 5.1.6 Renin Inhibitors

      7. 5.1.7 Calcium Channel Blockers

      8. 5.1.8 Other Therapeutic Classes

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Middle East and Africa

        1. 5.2.4.1 GCC

        2. 5.2.4.2 South Africa

        3. 5.2.4.3 Rest of Middle East and Africa

      5. 5.2.5 South America

        1. 5.2.5.1 Brazil

        2. 5.2.5.2 Argentina

        3. 5.2.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca PLC

      2. 6.1.2 C.H. Boehringer Sohn AG & Ko. KG

      3. 6.1.3 Daiichi Sankyo Company Limited

      4. 6.1.4 Johnson & Johnson

      5. 6.1.5 Lupin Limited

      6. 6.1.6 Merck & Co. Inc.

      7. 6.1.7 Novartis International AG

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 Ranbaxy Laboratories Limited

      10. 6.1.10 Sanofi SA

      11. 6.1.11 Noden Pharma DAC

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Anti-hypertensive Drugs Market market is studied from 2018 - 2026.

The Global Anti-hypertensive Drugs Market is growing at a CAGR of 4.5% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Pfizer Inc., C.H. Boehringer Sohn AG & Ko. KG, Noden Pharma DAC, Merck & Co. Inc., Daiichi Sankyo Company Limited are the major companies operating in Global Anti-hypertensive Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!